<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03432286</url>
  </required_header>
  <id_info>
    <org_study_id>16352</org_study_id>
    <secondary_id>I5Q-MC-CGAS</secondary_id>
    <secondary_id>2017-004351-23</secondary_id>
    <nct_id>NCT03432286</nct_id>
  </id_info>
  <brief_title>A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine</brief_title>
  <acronym>REBUILD</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age With Episodic Migraine - the REBUILD Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to determine the safety and efficacy of the study drug
      galcanezumab in participants 6 to 17 years of age with episodic migraine.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 31, 2018</start_date>
  <completion_date type="Anticipated">December 26, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in the Number of Monthly Migraine Headache Days</measure>
    <time_frame>Baseline, 3 Months</time_frame>
    <description>Change from baseline in the number of monthly migraine headache days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with Reduction from Baseline ≥50% in Monthly Migraine Headache Days</measure>
    <time_frame>3 Months</time_frame>
    <description>Proportion of participants with reduction from baseline ≥50% in monthly migraine headache days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Number of Monthly Headache Days with Nausea and/or Vomiting</measure>
    <time_frame>Baseline, 3 Months</time_frame>
    <description>Change from baseline in the number of monthly headache days with nausea and/or vomiting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Number of Monthly Headache Days with Photophobia and Phonophobia</measure>
    <time_frame>Baseline, 3 Months</time_frame>
    <description>Change from baseline in the number of monthly headache days with photophobia and phonophobia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Number of Monthly Migraine Headaches with Prodromal Symptoms</measure>
    <time_frame>Baseline, 3 Months</time_frame>
    <description>Change from baseline in the number of monthly migraine headaches with prodromal symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Number of Days on Which Acute Migraine Treatments are Taken per Month</measure>
    <time_frame>Baseline, 3 Months</time_frame>
    <description>Change from baseline in the number of days on which acute migraine treatments are taken per month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression-Improvement (PGI-I) Rating</measure>
    <time_frame>3 Months</time_frame>
    <description>PGI-I rating</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Number of Monthly Headache Days</measure>
    <time_frame>Baseline, 3 Months</time_frame>
    <description>Change from baseline in the number of monthly headache days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on the Pediatric Quality of Life Inventory (PedsQL) Total Score</measure>
    <time_frame>Baseline, 3 Months</time_frame>
    <description>Change from Baseline on the PedsQL total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on the Pediatric Migraine Disability Assessment test (PedMIDAS) Total Score</measure>
    <time_frame>Baseline, 3 Months</time_frame>
    <description>Change from baseline on the PedMIDAS total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on the Patient Satisfaction with Medication Questionnaire-Modified (PSMQ-M)</measure>
    <time_frame>Baseline, 3 Months</time_frame>
    <description>Change from baseline on the PSMQ-M</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Suicidal Ideation and Behaviors Assessed by the Columbia Suicide Severity Rating Scale (C-SSRS) Score</measure>
    <time_frame>Baseline through 3 Months</time_frame>
    <description>Percentage of Participants with Suicidal Ideation and Behaviors Assessed by the C-SSRS Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Serum Concentration of Galcanezumab</measure>
    <time_frame>Baseline through 3 Months</time_frame>
    <description>PK: Serum concentration of galcanezumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of Calcitonin Gene-Related Peptide (CGRP)</measure>
    <time_frame>Baseline through 3 Months</time_frame>
    <description>Plasma concentration of CGRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Developing Anti-Drug Antibodies</measure>
    <time_frame>Baseline through 3 Months</time_frame>
    <description>Percentage of participants developing anti-drug antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants who Initiate Migraine Prevention Medication</measure>
    <time_frame>16 Months</time_frame>
    <description>Proportion of participants who initiate migraine prevention medication</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">224</enrollment>
  <condition>Episodic Migraine</condition>
  <arm_group>
    <arm_group_label>Galcanezumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Galcanezumab administered by subcutaneous (SQ) injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered by SQ injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Galcanezumab</intervention_name>
    <description>Administered SQ</description>
    <arm_group_label>Galcanezumab</arm_group_label>
    <other_name>LY2951742</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SQ</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a diagnosis of migraine as defined by the International Headache Society
             International Classification of Headache Disorders (IHS ICHD-3) beta guidelines (1.1
             or 1.2) (ICHD-3 2013), with a history of migraine headaches of at least 6 months prior
             to screening.

        Exclusion Criteria:

          -  Participants who are taking, or are expected to take, therapeutic antibodies during
             the course of the study (adalimumab, infliximab, trastuzumab, bevacizumab, etc.).
             Prior use of therapeutic antibodies, other than antibodies to calcitonin gene-related
             peptide (CGRP) or its receptor, is allowed if that use was more than 12 months prior
             to baseline.

          -  Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic
             proteins, or to galcanezumab or its excipients.

          -  Current use or prior exposure to galcanezumab, another CGRP antibody, or CGRP receptor
             antibody, including those who have previously completed or withdrawn from this study
             or any other study investigating a CGRP antibody.

          -  History of persistent daily headache, cluster headache or migraine subtypes including
             hemiplegic (sporadic or familial) migraine and migraine with brainstem aura
             (previously basilar-type migraine) as defined by IHS ICHD-3 beta.

          -  History of any type of headache except for migraine, tension type headache, or
             medication overuse headache, as defined by IHS ICHD-3 beta, in the 3 months prior to
             randomization. For example, a history of post-traumatic headache in this 3-month
             period would not be allowed.

          -  History of traumatic head injury, associated with significant change in the quality or
             frequency of their headaches, including new onset of migraine following traumatic head
             injury.

          -  Participants with a known history of intracranial tumors or developmental
             malformations including Chiari malformations.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>Clinicaltrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical Center for Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>619-521-2830</phone>
    </contact>
    <investigator>
      <last_name>William Koltun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions Inc</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>904-281-5757</phone>
    </contact>
    <investigator>
      <last_name>Nandita Jones</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Psychiatric Inst of Florida-Clinical Neuroscience Solutions</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>407-425-5100</phone>
    </contact>
    <investigator>
      <last_name>Linda Harper</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Premiere Research Institute at Palm Beach Neurology</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>561-845-0500</phone>
    </contact>
    <investigator>
      <last_name>Paul Winner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlanta Center of Medical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>404-881-5800</phone>
    </contact>
    <investigator>
      <last_name>Robert Riesenberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alexian Brothers Medical Center</name>
      <address>
        <city>Hoffman Estates</city>
        <state>Illinois</state>
        <zip>60169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>847-593-8553</phone>
    </contact>
    <investigator>
      <last_name>Hossam AbdelSalam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>919-668-4000</phone>
    </contact>
    <investigator>
      <last_name>Klaus Werner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Childrens Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>513-636-4222</phone>
    </contact>
    <investigator>
      <last_name>Marielle Kabbouche-Samaha</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>215-590-1419</phone>
    </contact>
    <investigator>
      <last_name>Christina Szperka</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Preferred Primary Care Physicians</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>412-650-6155</phone>
    </contact>
    <investigator>
      <last_name>Nathan Bennett</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Clinical Research Center</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98007-4209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>425-453-0404</phone>
    </contact>
    <investigator>
      <last_name>Arifulla Khan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Office of Dr. Samuel Sanchez PSC</name>
      <address>
        <city>Caguas</city>
        <zip>00727</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>7877463136</phone>
    </contact>
    <investigator>
      <last_name>Karen Cruz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.lillytrialguide.com/en-US/studies/migraine/CGAS#?postal=</url>
    <description>A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2018</study_first_submitted>
  <study_first_submitted_qc>February 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 14, 2018</study_first_posted>
  <last_update_submitted>March 12, 2018</last_update_submitted>
  <last_update_submitted_qc>March 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.
This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

